Journal of Cardiac Failure最新文献

{"title":"Predicted Heart Mass and Outcomes in the Contemporary Era of Heart Transplantation: Insights from the Dallas Heart Study.","authors":"Ersilia M Defilippis, Lauren K Truby, Sonia Garg, Elaine Wu, Hadi Beaini, Matthias Peltz, Mark H Drazner, Natalie Bello, Maryjane A Farr","doi":"10.1016/j.cardfail.2025.01.023","DOIUrl":"10.1016/j.cardfail.2025.01.023","url":null,"abstract":"<p><strong>Background: </strong>Donor-recipient size matching is a key factor in donor selection for heart transplantation (HT). One approach uses predicted heart mass (PHM), derived from the Multi-Ethnic Study of Atherosclerosis (MESA). We sought to examine whether predicted left ventricular mass (PLVM) derived from the Dallas Heart Study (DHS) is associated with post-transplant outcomes.</p><p><strong>Methods: </strong>The study cohort included participants without pre-existing cardiac disease in the DHS who had cardiac MRIs (n = 1746). A PLVM model was derived by linear regression. The DHS PLVM and MESA PHM were tested for correlation. The associations of the DHS PLVM and the MESA PHM with 1-year mortality post-HT were assessed in the United Network for Organ Sharing Registry in 3 eras: era 1: 1/1/2011-12/31/2014; era 2: 1/1/2015-10/17/2018; and era 3: 10/18/2018-12/31/2021). A pre-specified threshold for low donor-to-recipient mass ratio (< 0.86) was used in Kaplan-Meier survival estimation and univariate and multivariable Cox proportional hazard models.</p><p><strong>Results: </strong>The DHS cohort had a median age of 43 (IQR 36-52) years, 49% male, 40% Black, and 18% Hispanic ethnicity. The DHS PLVM was highly correlated with the MESA PHM: r = 0.96; P < 0.001. In era 1, a low donor-to-recipient mass ratio according to the DHS PLVM was associated with increased 1-year mortality rates (log-rank P < 0.001) as was the MESA PHM (log rank P = 0.002). However, in eras 2 and 3, a low donor-to-recipient mass ratio by either the DHS PLVM or MESA PHM was not associated with increased 1-year mortality rates.</p><p><strong>Conclusion: </strong>PLVM was highly correlated with PHM. A low donor-to-recipient mass ratio, whether assessed by PLVM or PHM, was associated with 1-year mortality post-HT in a historical era but not in the current era under the new allocation system. These findings suggest that other factors may be contributing to donor selection and mortality risk in the modern era.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of GLP-1 Receptor Agonists in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.","authors":"Saad Ahmed Waqas, Muhammad Umer Sohail, Muhammad Saad, Abdul Mannan Khan Minhas, Stephen J Greene, Marat Fudim, Gregg C Fonarow, Dmitry Abramov, Muhammad Shahzeb Khan, Raheel Ahmed","doi":"10.1016/j.cardfail.2025.01.022","DOIUrl":"10.1016/j.cardfail.2025.01.022","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) with mildly reduced or preserved ejection fraction (HFpEF) accounts for over half of cases of HF, with obesity playing a key role. Residual risk remains high despite available therapies. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown potential cardiometabolic benefits, but their role in HFpEF remains unclear.</p><p><strong>Methods: </strong>A systematic review and meta-analysis of randomized controlled trials evaluating GLP-1RAs in HFpEF were conducted. Studies evaluating GLP-1RA in combination with glucose-dependent insulinotropic polypeptide (GIP) were also included. The analyzed outcomes included cardiovascular (CV) death, worsening HF events and their composite. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled by using a random-effects model.</p><p><strong>Results: </strong>Six randomized controlled trials involving 8788 patients were included. GLP-1RAs significantly reduced the composite outcome of CV death or worsening HF events (HR: 0.68 [0.51-0.89]; P = 0.006, I² = 47%) as well as worsening HF events alone (HR: 0.56 [0.38-0.82]; P = 0.003, I² = 51%). No significant reduction was observed for CV death alone (HR: 0.86 [0.67-1.12]; P = 0.27, I² = 0%).</p><p><strong>Conclusion: </strong>GLP-1RAs reduce worsening HF events and the composite of CV death or worsening HF in HFpEF, particularly in patients with obesity or diabetes. These findings support their role as a promising therapy requiring further HFpEF-focused trials.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143492019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Characteristics and Outcomes of Patients With Cardiogenic Shock and Clinically Significant Valvular Heart Disease: From the Critical Care Cardiology Trials Network.","authors":"Anthony P Carnicelli, P Elliott Miller, David D Berg, Nijat Aliyev, Carlos L Alviar, Erin A Bohula, Sunit-Preet Chaudhry, Meshe Chonde, Christine Chow, Howard A Cooper, Lori B Daniels, Christopher B Fordyce, Shahab Ghafghazi, Michael J Goldfarb, Kari L Gorder, Madeleine M Hamilton, Ryan R Keane, Michael C Kontos, Jonathan J Kusner, Evan Leibner, Daniel B Loriaux, Venu Menon, Raunak M Nair, L Kristin Newby, Mary-Tiffany Oduah, Michael G Palazzolo, Harsh Patolia, Jacob B Pierce, Matthew J Pierce, Brian J Potter, Alastair Proudfoot, Robert O Roswel, Gregory Schnell, Jeffrey Shaw, Kiran Sidhu, Shashank S Sinha, Anubodh S Varshney, Jason N Katz, Sean VAN Diepen, David A Morrow","doi":"10.1016/j.cardfail.2025.01.019","DOIUrl":"10.1016/j.cardfail.2025.01.019","url":null,"abstract":"<p><strong>Background: </strong>Cardiogenic shock (CS) can be complicated by severe valvular heart disease (VHD). We analyzed cardiac intensive care unit (CICU) admissions according to VHD status.</p><p><strong>Methods and results: </strong>The Critical Care Cardiology Trials Network is a multicenter network of tertiary CICUs. Centers contributed data from consecutive admissions during 2-month annual snapshots from 2017-2023. CS admissions were classified as having CS attributed to VHD, CS with noncausative VHD or CS without severe VHD. Demographics and therapies were compared. Unadjusted and adjusted odds ratios for in-hospital mortality were calculated. We analyzed 5242 admissions with CS (4.1% attributed to VHD, 18.8% with noncausative VHD, 77.1% without severe VHD). Mitral regurgitation (32.1%) and aortic stenosis (27.9%) were the most common pathologies in CS attributed to VHD. Admissions with CS attributed to VHD more commonly had LVEF ≥ 40% on admission (present in 62.8%, 22.6% and 15.1%, respectively; P < 0.001). Valve intervention was performed in 32.1% of those with CS attributed to VHD. Unadjusted in-hospital mortality in admissions with CS attributed to VHD was 40.0%, compared to 33.4% and 30.3% in the other groups.</p><p><strong>Conclusions: </strong>VHD is the underlying cause of CS in a minority of CICU admissions but is associated with high in-hospital mortality rates.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143458131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Role of Heart Failure Physicians in the Contemporary Cardiac Intensive Care Unit: Impact on Heart Failure as a Career Choice Among Fellowship Applicants.","authors":"Nir Uriel, Justin Fried, Adil Yunis, Kevin Clerkin, Dor Lotan, Boaz Elad, Nancy Kelly, Jayant Raikhelkar, Daniel Burkhoff, Martin Leon, Manreet K Kanwar, Gabriel T Sayer","doi":"10.1016/j.cardfail.2025.02.006","DOIUrl":"10.1016/j.cardfail.2025.02.006","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mitigating Post-operative Right Ventricular Dysfunction After Left Ventricular Assist Device: The RV Protection Study.","authors":"Anthony J Kanelidis, Leo Gozdecki, Mark N Belkin, Sara Kalantari, Ann Nguyen, Ben B Chung, Stanley Swat, Nitasha Sarswat, Gene Kim, Krystina Chickerillo, Justin Okray, Annalyse Hubbell, Shana K Creighton, Christine Y Jung, Indra Bole, Seyed Ehsan Saffari, Michael O'Connor, Takeyoshi Ota, Valluvan Jeevanandam, Christopher Salerno, Jonathan Grinstein","doi":"10.1016/j.cardfail.2025.01.017","DOIUrl":"10.1016/j.cardfail.2025.01.017","url":null,"abstract":"<p><strong>Background: </strong>Despite improvements in hemocompatibility-related adverse events (HRAEs) with the HeartMate 3 left ventricular assist device (LVAD), hemodynamic-related events (HDREs), such as right ventricular failure (RVF) and aortic insufficiency, still result in considerable morbidity and mortality. We investigated a comprehensive, upfront RV protection strategy combining hemodynamic, ventilatory and pharmaceutical optimization to mitigate the risk of RVF.</p><p><strong>Methods/results: </strong>Participants were prospectively randomized in a 1:1 fashion to either the RV-protection strategy or usual care for post-operative LVAD management. The RV-protection strategy targeted RV afterload (inhaled NO ≥ 48 hrs, PCWP < 18), RV preload (CVP 8-14), RV perfusion (MAP 70-90, Hgb > 8), RV contractility (IV inotropes), rate/rhythm control (HR >100, normal sinus), ventilatory management (SpO2 >95, PaCO² < 50, plateau pressure < 30, PEEP ≤ 5), and RV geometry (echo-guided septal position). The primary outcome was survival free from any HDREs or HRAEs at 24 weeks. Secondary outcomes included severe RVF, according to INTERMACS and ARC definitions. Twenty participants were randomized: 10 to the RV-protection strategy and 10 to usual care. The median age was 60 years (IQR 54-69), 50% were Black, and 50% had ischemia. At 24 weeks, the RV-protection strategy showed significantly greater survival rates free from HDREs or HRAEs compared to usual care (80% vs 40%; P = 0.04). Event-free survival for HRAEs resulted in similar findings. No HDREs occurred with the RV protection strategy vs 3 (30%) with usual care (P = 0.067). Similarly, severe RVF according to INTERMACS or ARC did not occur in the RV protection strategy vs 3 (30%) in the usual-care cohort (P = 0.20).</p><p><strong>Conclusions: </strong>Participants receiving a novel, comprehensive, upfront RV protection strategy post-LVAD implantation had significantly greater survival rates free from HDREs or HRAEs at 24 weeks.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in Stressed Blood Volume With Endovascular Ablation of the Right Greater Splanchnic Nerve in Heart Failure With Preserved Ejection Fraction: The REBALANCE-HF Trial.","authors":"Husam M Salah, Marat Fudim, Barry A Borlaug, Sheldon E Litwin, Matthew Stark, Sanjiv J Shah, Daniel Burkhoff","doi":"10.1016/j.cardfail.2025.01.016","DOIUrl":"10.1016/j.cardfail.2025.01.016","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute Heart Failure: Transitioning From Symptom-Based Care to Remission.","authors":"Gad Cotter, Beth A Davison, Douglas L Mann, Jan Biegus, Jozine M Termaaten, Matteo Pagnesi, Yonathan Freund, Adriaan A Voors, Piotr Ponikowski, Marco Metra, Alexandre Mebazaa","doi":"10.1016/j.cardfail.2024.12.016","DOIUrl":"10.1016/j.cardfail.2024.12.016","url":null,"abstract":"<p><p>During the past century, the characteristics of patients with heart failure (HF) and acute HF (AHF) have shifted from patients with severe pump failure due to rheumatic, hypertensive and ischemic heart disease to older and more obese patients with multiple severe comorbidities. The pathophysiology of AHF has shifted, in parallel, from that of advanced, end-stage pump failure caused by severe left ventricular dysfunction to age, obesity and comorbidity-related cardiovascular dysfunction combined with neurohormonal and inflammatory dysregulation or \"inflammaging.\" With the advent of neurohormonal blockers leading to improved outcomes of patients with chronic HF, the focus of AHF therapy has also changed from care directed at early symptom improvement to therapies directed toward longer-term improvements in quality of life and outcomes. Studies conducted in the past 5 years suggest that the beneficial effects seen with the 4 pillars of guideline-directed medical therapy for HF, mostly comprising neurohormonal blockade, can be extended to AHF when these therapies are initiated and rapidly uptitrated during admission and after discharge. A recent pilot study, CORTAHF (Effect of Short-Term Prednisone Therapy on CRP Change in Emergency Department Patients With Acute Heart Failure and Elevated Inflammatory Markers), has suggested that these benefits can be extended by treating patients with AHF and markers of inflammatory activation with anti-inflammatory therapies. Future studies should further examine whether combined anti-inflammatory therapy and neurohormonal blockade can lead to the reversal of disrupted underlying pathophysiology and remission in patients with AHF.</p>","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425494","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcatheter Left Ventricular Restoration System: Ancora Heart Inc.","authors":"Yogita Rochlani, Enklajd Marsela, Ulrich P Jorde","doi":"10.1016/j.cardfail.2025.02.004","DOIUrl":"10.1016/j.cardfail.2025.02.004","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425466","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Analysis of Health Care Utilization With Baroreflex Activation Therapy for Heart Failure.","authors":"Jacob Abraham, Amarinder S Bindra, Marat Fudim, Pujan P Patel, Nirav Y Raval, Dmitry Yaranov, Fares Yared, Seth J Wilks, Stefanie Busgang, Philip B Adamson","doi":"10.1016/j.cardfail.2025.02.003","DOIUrl":"10.1016/j.cardfail.2025.02.003","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143425503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Increasing Evidence Supports the Benefits of Rapid Uptitration of the Neurohormonal Blockade in HFmrEF/HFpEF Patients With AHF.","authors":"Gad Cotter, Beth Davison, Jan Biegus, Matteo Pagnesi, Marco Metra, Javed Butler, Ovidiu Chioncel, Piotr Ponikowski, Alexandre Mebazaa","doi":"10.1016/j.cardfail.2024.12.015","DOIUrl":"10.1016/j.cardfail.2024.12.015","url":null,"abstract":"","PeriodicalId":15204,"journal":{"name":"Journal of Cardiac Failure","volume":" ","pages":""},"PeriodicalIF":6.7,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143414412","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}